AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Chimeric is advancing CHM 1301 program to the next stage of preclinical development.
- CHM 1301 is a next generation chlorotoxin (CLTX) chimeric antigen receptor (CAR) NK cell therapy.
- The therapy demonstrated highly promising efficacy in preclinical studies of in vitro models of human ovarian cancer and pancreatic cancer.
- CHM shares charged higher by 7%.
Chimeric Therapeutics Limited (ASX: CHM) shares gained over 7% on 28 November 2023 as the company announced additional information on its earlier update focused on positive in vitro data for CHM 1301.
The next generation CLTX CAR NK cell therapy program is entering the next phase of preclinical development. Under the study, the company plans to use armoured NK cell platform (CHM 0301) that was recently developed.
The study would aim to boost cell potency and resistance against the immunosuppressive solid tumour microenvironment.
In-depth details
CHM 1301 is a combination of the efficacy of CHM 1101 and off-the-shelf convenience of CHM 02012, reflecting the synergies of assets in the Chimeric portfolio.
It was tested in preclinical in vitro models of human ovarian cancer and pancreatic cancer, delivering extremely promising efficacy, as per the company.
In ovarian cancer, cell killing rose up to 260% versus first generation CHM 0201 cells. In pancreatic cancer, cell killing surged up to 300% as against the first generation CHM 0201 cells.
The entry into these new disease areas shows the potential of CLTX CAR therapies of the company against additional high-unmet need solid tumour types beyond glioblastoma.
Now CHM is progressing the CHM 1301 program to the next stage of preclinical development by use of its NK cell platform, to increase cell potency as well as resistance against the immunosuppressive solid tumor microenvironment.
CHM shares traded at AU$0.030 on 28 November 2023.
